Roche Hldg (RHHBY) Stock News

Roche (OTCQX:RHHBY) has announced mixed results from two clinical trials evaluating astegolimab for chronic obstructive pulmonary disease (COPD). The pivotal phase IIb ALIENTO study (n=1,301) met its primary endpoint, showing a 15.4% reduction in annualized exacerbation rate (AER) at 52 weeks. However, the phase III ARNASA study (n=1,375) missed its primary endpoint, showing only a numerical 14.5% reduction in AER.

Both trials tested astegolimab against placebo on top of standard care in moderate to very severe COPD patients, including both current and former smokers. While the safety profile remained consistent with previous data, the total number of exacerbations was lower than anticipated in both trials. Roche plans to discuss these results with regulatory authorities to determine next steps.

Genentech (OTCQX: RHHBY) received a Complete Response Letter (CRL) from the FDA regarding its supplemental Biologics License Application (sBLA) for Columvi in combination with GemOx for second-line DLBCL treatment. The FDA determined that the STARGLO study data was insufficient to support the proposed indication in U.S. patients.

Despite this setback, Columvi maintains its accelerated approval for third-line DLBCL treatment. The company is in discussions with the FDA about using the Phase III SKYGLO study as a new postmarketing requirement. The STARGLO study demonstrated a 41% reduction in death risk, and the combination is already approved in over 35 countries.

Roche (OTCQX: RHHBY) announced key leadership changes in its enlarged Corporate Executive Committee. Dr. Hans Clevers, Head of Roche Pharma Research and Early Development (pRED), will retire at the end of August 2025. Dr. Clevers, who joined the Board in 2019 and became pRED Head in March 2022, will continue leading the Institute of Human Biology until a successor is named.

Additionally, Barbara Schädler, Head of Group Communications, will retire from the company at the end of 2025. Schädler, who joined Roche in 2019, was credited with modernizing the company's communication function and leading the internal COVID-19 taskforce. The company will announce successors for both positions in due course.

Roche announced promising phase I/II data for NXT007, a next-generation bispecific antibody for hemophilia A treatment. The NXTAGE study showed NXT007 achieved zero treated bleeds in highest dose groups and demonstrated a tolerable safety profile with no thromboembolic events. The study included 30 participants aged 12-65 across four cohorts receiving subcutaneous NXT007 every 2-4 weeks. Three phase III studies are planned for 2026, including a head-to-head comparison with Roche's Hemlibra. NXT007 aims to provide haemostatic normalization and reduced treatment burden for patients. The drug leverages Roche's expertise in hemophilia A and bispecific antibody development, with additional phase II data expected later this year.

Roche announced significant results from the phase III SUNMO study for its Lunsumio and Polivy combination therapy in treating relapsed/refractory large B-cell lymphoma. The combination showed remarkable efficacy with 11.5 months median progression-free survival, three times longer than the comparison treatment R-GemOx. The therapy demonstrated a 59% reduction in disease progression risk and doubled the complete response rate at 51.4% versus 24.3% for R-GemOx. The treatment showed a favorable safety profile suitable for outpatient use, with low incidence of cytokine release syndrome. This novel combination of a bispecific antibody and antibody-drug conjugate avoids traditional chemotherapy and has been added to NCCN Guidelines as a category 2A recommendation for second-line DLBCL treatment in non-transplant patients.

Genentech's Phase III SUNMO study demonstrated significant success in treating relapsed/refractory large B-cell lymphoma using a combination of Lunsumio and Polivy. The treatment showed a median progression-free survival of 11.5 months, three times longer than the standard R-GemOx therapy, and reduced disease progression risk by 59%. The combination therapy achieved a 70.3% objective response rate and doubled complete response rate to 51.4% compared to R-GemOx. Notably, 72.6% of complete responders maintained remission after one year. The treatment showed a favorable safety profile suitable for outpatient use, with low incidence of cytokine release syndrome and no neurotoxicity syndrome events reported. This chemotherapy-free combination represents a potential breakthrough as the first bispecific antibody and antibody-drug conjugate treatment for LBCL, with results to be submitted to global health authorities including the FDA.

Genentech and AbbVie announced that their Phase III VERONA study investigating Venclexta (venetoclax) plus azacitidine for previously untreated higher-risk myelodysplastic syndromes (MDS) failed to meet its primary endpoint of overall survival. The global study involved approximately 500 patients across 220 sites, comparing Venclexta plus azacitidine to placebo plus azacitidine. While the safety profile aligned with known risks and showed no unexpected signals, the trial's failure represents a setback in the treatment development for higher-risk MDS patients. The companies plan to present complete data at an upcoming medical meeting in 2025, and the results do not affect Venclexta's currently approved indications or ongoing studies.

Genentech, a Roche Group company, has announced plans to advance prasinezumab, a first-in-class anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. The decision follows encouraging results from the Phase IIb PADOVA study and open-label extensions of both PADOVA and PASADENA trials. While the drug missed statistical significance in its primary endpoint of confirmed motor progression, it demonstrated potential clinical benefits when combined with symptomatic treatments. The studies provided the first biomarker evidence of prasinezumab affecting underlying disease biology, with positive trends in reduced motor progression at 104 weeks that appeared sustained over longer periods. Currently, over 750 people with early-stage Parkinson's are participating in ongoing long-term safety and efficacy studies.

Roche announced plans to advance prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. The decision follows encouraging results from the Phase IIb PADOVA study and open-label extensions of PADOVA and PASADENA studies. While the primary endpoint of time to confirmed motor progression missed statistical significance, the drug showed positive trends in reducing motor progression at 104 weeks, with effects appearing sustained over longer periods. The studies provided first biomarker evidence of prasinezumab impacting underlying disease biology. The development aims to address the needs of over 10 million Parkinson's disease patients globally, with prasinezumab potentially becoming the first disease-modifying treatment for the condition.